Welcome to our dedicated page for Genelux SEC filings (Ticker: GNLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page presents Genelux Corporation (NASDAQ: GNLX) SEC filings, offering insight into how the late clinical-stage biopharmaceutical company reports its activities as it develops oncolytic immunotherapies. Genelux focuses on next-generation oncolytic vaccinia virus immunotherapeutic product candidates, led by Olvi-Vec (olvimulogene nanivacirepvec), and its regulatory disclosures help investors follow governance, financing, and development-related matters.
Key filing types for GNLX include annual and quarterly reports, which discuss research and development efforts, clinical trial status for programs such as the OnPrime/GOG-3076 Phase 3 ovarian cancer trial, the VIRO-25 Phase 2 NSCLC trial, and the Olvi-Vec-SCLC-202 Phase 1b/2 SCLC trial, as well as risk factors and other business information. Definitive proxy statements (DEF 14A) provide details on board structure, director elections, equity incentive plans, and corporate governance practices, including matters submitted to stockholders at annual meetings.
Current reports on Form 8-K can describe material events such as changes to equity compensation terms, option repricing decisions under the company’s equity plans, or other board-approved actions. Registration statements and prospectus supplements associated with underwritten public offerings of common stock outline how Genelux raises capital to fund research and development, clinical trial expenses, and general corporate purposes.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as clinical program disclosures, equity plan changes, and stockholder voting outcomes. Real-time updates from EDGAR, along with access to ownership and compensation information contained in proxy materials and other filings, allow investors to monitor GNLX’s regulatory reporting as it advances its immuno-oncology pipeline.
Genelux Corporation director Mary Mirabelli received equity awards on 08/27/2025 consisting of 22,283 restricted stock units and a stock option for 28,576 shares. The RSUs convert to one share each upon vesting and will vest on the earlier of the one-year anniversary of grant or the company’s next annual meeting. The option has a $3.64 exercise price and expires 08/26/2035; the option shares vest on the same schedule as the RSUs.
After these grants Mirabelli beneficially owns 73,284 shares of common stock and 28,576 option shares. The awards were granted under the Issuer’s 2022 Equity Incentive Plan and appear intended as retention/compensation for a director role.
Genelux Corporation director Tyree James L reported insider grants and ownership changes on 08/27/2025. The filing discloses the grant of 22,283 restricted stock units (RSUs) under the Issuer's 2022 Equity Incentive Plan; each RSU represents the contingent right to receive one share of common stock upon vesting. After the RSU grant, the reporting person beneficially owned 68,074 shares.
The filing also shows an option grant of 28,576 stock options with a $3.64 exercise price, exercisable and expiring on 08/26/2035. The RSUs and options vest upon the earlier of the one-year anniversary of grant and the Issuer's next annual meeting of stockholders. The form was signed by an attorney-in-fact on 08/29/2025.
Joseph Cappello, Chief Technical Officer of Genelux Corporation (GNLX), reported insider awards and holdings following transactions dated 08/27/2025. He was granted 107,500 restricted stock units (RSUs) that convert to one share each upon vesting and received a stock option covering 142,500 shares with an exercise price of $3.64 and an expiration date of 08/26/2035. After these transactions he beneficially owns 159,766 shares of common stock and 142,500 option shares. The RSUs vest 25% after one year and then in 12 equal quarterly installments; the option vests 25% after one year and then in 36 equal monthly installments.